announced filing of a patent covering its proprietary method of implementing S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act in a manner which provides a novel means of safeguarding patients while allowing rapid access to experimental medications.
The patent application is based on the current Standard Operating Procedures of the Right to Try Foundation, which call for a physical or virtual independent Institutional Review Board assessment of each patient considered for an experimental medication.
"The fact that publicly this new pathway of providing hope to patients with no hope has only been used two times
[1] since the law was passed is appalling" said Famela Ramos, President and Founder of the Right to Try Foundation.
"Why are American patients with terminal illnesses travelling to hospitals outside the USA when so many experimental treatments are available here?
By establishing an independent means of ensuring patients are protected,
we believe that we solve the issue that many opponents of the law raise,
which is that patients will be victims of predatory companies."
The Right to Try Foundation seeks to accelerate medical progress by establishing means by which drugs that are demonstrated safe can be
used for different diseases or in combinations with other drugs based
on the ideas of the doctors and not the Pharmaceutical Companies.
Market Data 
Markets 
AI
